Gland Pharma Bags Mega CDMO Deal; Targets ₹840 Crore Annual Revenue
Source: ET Real Estate
Arth Insight · What this means for your wallet
- Gland Pharma has signed a major supply deal for 55 sterile injectable products with a global firm.
- The deal is expected to generate up to ₹840 crore in annual revenue at peak capacity.
- Commercial production and revenue flow are scheduled to commence in 2029.
Wealth-Impact Simulator
See what a one-time investment could grow to.
Indicative estimate for education only — not investment advice.
Explore investmentsHyderabad-based Gland Pharma has signed a major manufacturing agreement with a global pharmaceutical giant to produce 55 sterile injectable products. The deal is expected to generate annual revenues of $90-100 million (approx. ₹750-840 crore) starting from 2029.
- ▸Gland Pharma has signed a major supply deal for 55 sterile injectable products with a global firm.
- ▸The deal is expected to generate up to ₹840 crore in annual revenue at peak capacity.
- ▸Commercial production and revenue flow are scheduled to commence in 2029.
- ▸The manufacturing will be spread across three different sites to ensure scale and efficiency.
- ✓Gland Pharma has signed a major supply deal for 55 sterile injectable products with a global firm.
- ✓The deal is expected to generate up to ₹840 crore in annual revenue at peak capacity.
- ✓Commercial production and revenue flow are scheduled to commence in 2029.
- ✓The manufacturing will be spread across three different sites to ensure scale and efficiency.
Gland Pharma, a leading Indian generic injectable manufacturer, has secured a significant strategic Manufacturing and Supply Agreement with a top-tier global pharmaceutical company. This Contract Development and Manufacturing Organization (CDMO) deal involves the technology transfer, manufacturing, and supply of a wide range of sterile injectable products, marking a major milestone for the company’s long-term growth trajectory.
Scope and Scale of the Agreement
The agreement is extensive, covering 55 Stock Keeping Units (SKUs) that will be produced across three of Gland Pharma’s manufacturing sites. This diversification across multiple facilities ensures supply chain resilience and leverages the company's specialized infrastructure for complex injectables. The partnership focuses on high-demand sterile products, a segment where Gland Pharma has established global expertise.
Financial Impact and Timeline
While the deal is a significant win for the company's order book, the financial benefits will follow a long-term gestation period. Gland Pharma estimates that once commercialization is fully realized, the deal has the potential to bring in annualized revenues between $90 million and $100 million (roughly ₹750 crore to ₹840 crore). However, investors should note that revenue generation from this specific contract is slated to begin in the year 2029, following the completion of technology transfers and regulatory approvals.
What it Means for Investors
For retail investors and market observers, this deal reinforces Gland Pharma's position as a preferred partner for global pharma giants looking to outsource complex manufacturing. While the immediate impact on the quarterly balance sheet may be limited due to the 2029 start date, it provides long-term revenue visibility and validates the company's technical capabilities in the sterile injectables space. This move aligns with the broader trend of global firms shifting manufacturing bases to cost-effective, high-quality Indian CDMOs.
This report is for informational purposes only and does not constitute financial or investment advice.
Community Pulse · This story
How readers rate the outlook after reading this article. Anonymous · one vote per reader · updates live.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What is the total value of Gland Pharma's new deal?
The deal is expected to generate between $90 million and $100 million (approximately ₹750-840 crore) in annualized revenue once commercialization is complete.
When will Gland Pharma start earning from this agreement?
Revenue generation from this specific manufacturing and supply agreement is expected to begin in 2029.
What products are covered under this contract?
The contract covers 55 SKUs of sterile injectable products, which involve complex manufacturing and technology transfer.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
IIT Guwahati Develops 'E-Eye' to Detect Cancer-Causing Toxins in Drinking Water
Researchers at IIT Guwahati have created a portable optical sensing device called 'E-Eye' for instant on-site detection of heavy metals and toxicants in water. The technology supports the Jal Jeevan Mission's goal of providing safe drinking water to every Indian household.
Mumbai Luxury Homes Hit Record ₹18,512 Cr Sales in H1 2026
Mumbai's luxury housing market achieved a record ₹18,512 crore in sales during the first half of 2026. However, growth is expected to slow down due to a high base and a cautious economic outlook.
Govt to Ban Drugmakers for Mislabeling and Fraudulent Approvals Under New Rules
The Union Health Ministry has amended the Drugs Rules, 1945, to strictly bar pharmaceutical companies from selling products approved through false information. The new regulations empower authorities to debar manufacturers and distributors to ensure medicine safety for Indian consumers.
Related Stories
IIT Guwahati Develops 'E-Eye' to Detect Cancer-Causing Toxins in Drinking Water
Researchers at IIT Guwahati have created a portable optical sensing device called 'E-Eye' for instant on-site detection of heavy metals and toxicants in water. The technology supports the Jal Jeevan Mission's goal of providing safe drinking water to every Indian household.
Mumbai Luxury Homes Hit Record ₹18,512 Cr Sales in H1 2026
Mumbai's luxury housing market achieved a record ₹18,512 crore in sales during the first half of 2026. However, growth is expected to slow down due to a high base and a cautious economic outlook.
Govt to Ban Drugmakers for Mislabeling and Fraudulent Approvals Under New Rules
The Union Health Ministry has amended the Drugs Rules, 1945, to strictly bar pharmaceutical companies from selling products approved through false information. The new regulations empower authorities to debar manufacturers and distributors to ensure medicine safety for Indian consumers.
Indian Pharma Alliance Urges Regularisation for Decade-Old Unapproved Drugs
The Indian Pharmaceutical Alliance (IPA) is pushing drug authorities to regularise numerous 'legacy drugs' that have been sold in the market for over a decade without central regulatory approval. This move aims to close long-standing regulatory gaps affecting common medicines like sodium valproate and carbamazepine tablets.